OTTAWA, ON / ACCESSWIRE / March 25, 2014 / Avivagen
Inc. (TSXV: VIV), a wellness company developing and delivering
products that support and enhance the health and quality of life
for animals and the people who care for them, announces an
agreement with the National Institute of Animal Sciences for
Vietnam to conduct a trial of OxC-beta as a non-antibiotic growth
promoter for swine.
The trial will test the efficacy of OxC-beta to maintain and
enhance the health and growth of pigs across their full post-wean
growth cycle. The response to the addition of OxC-beta in the diet
will be recorded via measurement of a series of health and
commercial measures. Such measures will include, but not be limited
to, weight gain, feed conversion efficiency, incidence of diarrhea
and disease-related mortality.
The trial is entitled "Evaluation of OxC-beta as a Growth
Promoting Health Supplement for Swine." Its testing of OxC-beta
will include five study arms: three feeding-levels of OxC-beta, a
negative control and a commercial antibiotic growth promoter (AGP)
control. The trial was designed by Professor La Van Kinh of the
National Institute of Animal Sciences for Vietnam, Professor
William Riley of Jinan University of Guangzhou, China and Avivagen
executives. The trial, which will be conducted by Professor Kinh at
the Institute and is expected to be completed before the end of
calendar 2014, is intended to support registrations for this
usage.
Cameron Groome, CEO and President, commented on Avivagen's
objectives with respect to this trial "Previously, OxC-beta was
tested for a shorter dosing period in weaned piglets. While the
results of that Canadian piglet study were very positive, they have
not been reconfirmed by way of another study, nor have the benefits
of OxC-beta been measured for older swine. This trial should
accomplish both those goals, along with helping to establish the
feeding levels that are most effective and economic."
Cameron also commented on other ongoing and planned studies of
OxC-beta "This study is the first Avivagen-sponsored trial of
OxC-beta to be conducted in 2014. While there are also multiple
trials being designed and run directly by our prospective
customers, it is the Avivagen-sponsored studies that will provide
publishable results to support multiple national product
registrations. Unlike Avivagen-sponsored trials, any positive
results of customer-sponsored OxC-beta trials might not be reported
other than by way of product sales."
As a country, Vietnam is the world's sixth-largest user of swine
feed - estimated by Pig International magazine at 8.75 million
metric tons of feed in 2012. In comparison, Canada ranks as number
seven in 2012, using 7.36 million metric tons. Avivagen's pricing
for the addition of OxC-beta to swine feed will be set in dollars
per ton of feed and dependent on efficacy and the selected level of
addition. Pricing of OxC-beta supplementation is expected to be
competitive with other growth-promoting feed additives, including
antibiotic and non-antibiotic options.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Livestock Productivity and Pet
Wellness.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - in Ottawa, Ontario and
Charlottetown, Prince Edward Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta
compounds occur naturally as carotenoid oxidation products in
vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research and study results indicate OxC-beta supports innate
immune function, which can help maintain good health. In pets,
OxC-beta supports overall vitality and energy, mobility and joint
function, skin, coat and gut. Results observed in food animals have
included healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are OxC-beta for livestock,
Vivamune(TM) Health Chews and Oximunol(TM) Chewables.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
About Vivamune(TM) Health Chews - For dogs and
cats
Vivamune(TM) Health Chews, containing Avivagen's proprietary
active ingredients, are scientifically-formulated chews for dogs
and cats. Vivamune(TM) Health Chews work with a pet's own immune
system to maintain overall health and well-being. They are sold in
re-sealable packages of 30 chews and are currently available in the
United States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM) Chewables - For dogs
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are distributed by Bayer
Healthcare LLC and are available through veterinarians for dogs of
all ages in the United States.
Forward Looking Statements
This document includes certain forward-looking statements that
are based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. Statements relating to
expectations regarding access to new markets, new or increased
revenue streams, Avivagen's ability to secure additional clinical
trials and customer relationships and the results of such trials
and relationships and Avivagen's intention to identify suitable
technology license opportunities are all examples of
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties that could cause actual
results or events to differ materially from current expectations.
Avivagen's products may not gain market acceptance in new markets,
new or expected revenue streams may not materialise in the near
term or at all, Avivagen may not be able to secure clinical trials
or new customer relationships and the results of such trials and
relationships may not be favourable. Unless required by law,
Avivagen Inc. assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking statements.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
c.groome@avivagen.com
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
SOURCE: Avivagen Inc.
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jul 2023 to Jul 2024